Efficacy and safety of ultra-long-acting insulin degludec

Therapeutic Advances in Endocrinology and Metabolism

Volumn 3, Issue 2, 2012, Pages 55-59

  Wakil, Ammar ^a   Atkin, Stephen L ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

hypoglycaemia; insulin degludec; type 1 and type 2 diabetes; ultra long acting basal insulin

Indexed keywords

HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN GLARGINE; ORAL ANTIDIABETIC AGENT;

DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84859336766     PISSN: 20420188     EISSN: 20420196     Source Type: Journal    
DOI: 10.1177/2042018812437181     Document Type: Review

References (15)

1. Atkin S.L. Bain S. Gough S. Shestakova M. Raz I. Blonde L. et al. (2011) Insulin degludec does not compromise efficacy or safety when given in a flexible once-daily dosing regimen compared to insulin glargine once daily at the same time each day in type 2 diabetes. Diabetologia 54 (Suppl. 1): 542.
2. Birkeland K.I. Home P.D. Wendisch U. Ratner R.E. Johansen T. Endahl L.A. et al. (2011 a) Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 34: 661–665.
3. Birkeland K.I. Raz I. Gough S. Atkin S.L. Shestakova M. Blonde L. et al. (2011 b) Insulin degludec in a flexible daily dosing regimen provides similar glycaemic control without increasing rates of hypoglycaemia compared to dosing the same time daily in type 2 diabetes. Diabetologia 54 (Suppl. 1): S423 (1041-P).
4. Donnelly L.A. Morris A.D. Evans J.M.M. for the DARTS/MEMO collaboration (2007) Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM 100: 345–350.
5. Heise T. Hermanski L. Nosek L. Feldmann A. Rasmussen S. Stryhn T. et al. (2010) Insulin degludec: less pharmacodynamic variability than insulin glargine under steady state conditions. Diabetologia 53 (Suppl. 1): S 387.
6. Hollander P. King A. Francisco A.M.O. Endahl L.A. Garber A. (2011) Basal-bolus therapy with insulin degludec improves long-term glycaemic control with fewer nocturnal hypoglycaemic events compared with insulin glargine in people with type 2 diabetes. Diabetologia 54 (Suppl. 1): S421 (1035-P).
7. Jonassen I. Havelund S. Ribel U. Hoeg-Jensen T. Steensgaard D. Johansen T. et al. (2010) Insulin degludec is a new generation ultra-long acting basal insulin with a unique mechanism of protraction based on multi-hexamer formation. Diabetes 59 (Suppl. 1): A11.
8. Niskanen L. Leiter L.A. Franek K. Weng J. Damci T. Muñoz Torres M. et al. (2011) IDegAsp, a soluble insulin combination of ultra-long-acting insulin degludec and insulin aspart, in type 2 diabetes: comparison with biphasic insulin aspart 30. In: Proceedings of the World Diabetes Congress 2011. Dubai: IDF.
9. Peyrot M. Rubin R.R. Kruger D.F. Travis L.B. (2010) Correlates of insulin injection omission. Diabetes Care 33: 240–245.
10. Polonsky W.H. Fisher L. Guzman S. Villa-Caballero L. Edelman S.V. (2005) Psychological insulin resistance in patients with type 2 diabetes. Diabetes Care 28: 2543–2545.
11. Randlov J. Poulsen J.U. (2008) How much do forgotten insulin injections matter to hemoglobin a1c in people with diabetes? A simulation study. J Diabetes Sci Technol 2: 229–235.
12. Riddle M.C. (2002) The underuse of insulin therapy in North America. Diabetes Metab Res Rev 18 (Suppl. 3): S42–S49.
13. Russell-Jones D. Francisco A.M.O. Pei H. Heller S. (2011) Basal-bolus therapy with insulin degludec improves long-term glycaemic control with less nocturnal hypoglycaemia compared with insulin glargine in type 1 diabetes. Diabetologia 54 (Suppl. 1): S425 (1045-P).
14. Wild D. von Maltzahn R. Brohan E. Christensen T. Clauson P. Gonder-Frederick L. (2007) A critical review of the literature on fear of hypoglycemia in diabetes: Implications for diabetes management and patient education. Patient Educ Counseling 68: 10–15.
15. Zinman B. Fulcher G. Rao P.V. Thomas N. Endahl L.A. Johansen T. et al. (2011) Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet 377: 924–931.